News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bourne Partners Advises Desitin Pharmaceuticals GmbH In Product Sale



4/19/2006 4:49:19 PM

Bourne Partners has advised Desitin Arzneimittel Gmbh (“Desitin” or the “Company”) on the sale of the Italian rights to Orfiril®-long (sodium valproate) to BiofuturaFarma S.p.A., a division of Sigma-tau, S.p.A., a leading Italian pharmaceutical company with annual sales in excess of $800 million.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES